MedTrace Logo

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

NCT00238446 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-02-24

No results posted yet for this study

Summary

This purpose of this extension study of patients being treated with EC-MPS is to assess the long term safety of this medication.

Conditions

  • Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Interventions

DRUG

EC-MPS

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2006-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238446 on ClinicalTrials.gov